{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:16:51Z","timestamp":1781533011004,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T00:00:00Z","timestamp":1479340800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00059-016-4496-3","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T08:17:30Z","timestamp":1479370650000},"page":"655-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Neuerungen der ESC-Leitlinien zur akuten und chronischen Herzinsuffizienz 2016","The new ESC Guidelines for acute and chronic heart failure 2016"],"prefix":"10.1007","volume":"41","author":[{"given":"C. U.","family":"Oeing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tsch\u00f6pe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,17]]},"reference":[{"key":"4496_CR1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et\u00a0al (2016) 2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (esc)developed with the special contribution of the heart failure association (hfa) of the esc. Eur Heart J 37:2129\u20132200","journal-title":"Eur Heart J"},{"key":"4496_CR2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD et\u00a0al (2012) Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (hfa) of the esc. Eur Heart J 33:1787\u20131847","journal-title":"Eur Heart J"},{"key":"4496_CR3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM et\u00a0al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251\u2013259","journal-title":"N Engl J Med"},{"key":"4496_CR4","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","volume":"33","author":"C Berry","year":"2012","unstructured":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), Berry C, Doughty RN, Granger C et al (2012) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Eur Heart J 33:1750\u20131757","journal-title":"Eur Heart J"},{"key":"4496_CR5","first-page":"996","volume":"175","author":"Y Gerber","year":"2015","unstructured":"Gerber Y, Weston SA, Redfield MM et\u00a0al (2015) A contemporary appraisal of the heart failure epidemic in olmsted county, minnesota, 2000 to 2010. JAMA 175:996\u20131004","journal-title":"JAMA"},{"key":"4496_CR6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jchf.2014.04.006","volume":"2","author":"W Ouwerkerk","year":"2014","unstructured":"Ouwerkerk W, Voors AA, Zwinderman AH (2014) Factors influencing the predictive power of models for predicting mortality and\/or heart failure hospitalization in patients with heart failure. JACC Heart Fail 2:429\u2013436","journal-title":"JACC Heart Fail"},{"key":"4496_CR7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Dahlstrom U, Filippatos G et al (2013) Eurobservational research programme: Regional differences and 1\u2011year follow-up results of the heart failure pilot survey (esc-hf pilot). Eur J Heart Fail 15:808\u2013817","journal-title":"Eur J Heart Fail"},{"key":"4496_CR8","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.1016\/j.hfc.2014.05.002","volume":"10","author":"CS Lam","year":"2014","unstructured":"Lam CS, Pieske B (2014) Heart failure with preserved ejection fraction(hfpef) currently represents one of the greatest unmet needs in cardiology. Introduction. Heart Fail Clin 10:xv. doi: 10.1016\/j.hfc.2014.05.002","journal-title":"Heart Fail Clin"},{"key":"4496_CR9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jchf.2016.03.013","volume":"4","author":"C Tschope","year":"2016","unstructured":"Tschope C, Pieske B (2016) \u201eOne size does not fit all\u201c: How to individualize decongestive therapy strategies in heart failure. JACC Heart Fail 4:460\u2013463","journal-title":"JACC Heart Fail"},{"key":"4496_CR10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0735-1097(03)00309-7","volume":"41","author":"A Nohria","year":"2003","unstructured":"Nohria A, Tsang SW, Fang JC et\u00a0al (2003) Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J\u00a0Am Coll Cardiol 41:1797\u20131804","journal-title":"J Am Coll Cardiol"},{"key":"4496_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejheart.2005.01.004","volume":"7","author":"LW Stevenson","year":"2005","unstructured":"Stevenson LW (2005) Design of therapy for advanced heart failure. Eur J Heart Fail 7:323\u2013331","journal-title":"Eur J Heart Fail"},{"key":"4496_CR12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9149(67)90023-9","volume":"20","author":"T Killip 3rd","year":"1967","unstructured":"Killip T 3rd, Kimball JT (1967) Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 20:457\u2013464","journal-title":"Am J Cardiol"},{"key":"4496_CR13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijcard.2014.08.007","volume":"176","author":"C Madamanchi","year":"2014","unstructured":"Madamanchi C, Alhosaini H, Sumida A, Runge MS (2014) Obesity and natriuretic peptides, bnp and nt-probnp: Mechanisms and diagnostic implications for heart failure. Int J Cardiol 176:611\u2013617","journal-title":"Int J Cardiol"},{"key":"4496_CR14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00059-007-3038-4","volume":"32","author":"M Naghavi","year":"2007","unstructured":"Naghavi M (2007) Preventive cardiology: The shape of the future. A synopsis from the screening for heart attack prevention and education (shape) task force report. Herz 32:356\u2013361","journal-title":"Herz"},{"key":"4496_CR15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00059-015-4213-7","volume":"40","author":"P Zimmer","year":"2015","unstructured":"Zimmer P, Bloch W (2015) Physical exercise and epigenetic adaptations of the cardiovascular system. Herz 40:353\u2013360","journal-title":"Herz"},{"key":"4496_CR16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00059-006-2782-1","volume":"31","author":"A Flaa","year":"2006","unstructured":"Flaa A, Kjeldsen SE (2006) Are all the hypertensives made equal? Herz 31:323\u2013330","journal-title":"Herz"},{"key":"4496_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpw087","author":"JM Flack","year":"2016","unstructured":"Flack JM, Nolasco C, Levy P (2016) The case for low blood pressure targets. Am J Hypertens. doi: 10.1093\/ajh\/hpw087","journal-title":"Am J Hypertens"},{"key":"4496_CR18","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr.","year":"2015","unstructured":"Wright JT Jr., Williamson JD, Whelton PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103\u20132116","journal-title":"N Engl J Med"},{"key":"4496_CR19","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575\u20131585","journal-title":"N Engl J Med"},{"key":"4496_CR20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ahj.2016.03.024","volume":"178","author":"H Frohlich","year":"2016","unstructured":"Frohlich H, Nelges C, Tager T et al (2016) Long-term changes of renal function in relation to ace inhibitor\/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Am Heart J 178:28\u201336","journal-title":"Am Heart J"},{"key":"4496_CR21","unstructured":"Kjeldsen SE (2016) European Society of Cardiology (ESC) Congress, Rom, 27\u201331 Aug."},{"key":"4496_CR22","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et\u00a0al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"4496_CR23","first-page":"1095","volume":"374","author":"G Derosa","year":"2016","unstructured":"Derosa G, Maffioli P (2016) Lixisenatide in type 2 diabetes and acute coronary syndrome. N Engl J Med 374:1095","journal-title":"N Engl J Med"},{"key":"4496_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et\u00a0al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. doi: 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"4496_CR25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322","journal-title":"N Engl J Med"},{"key":"4496_CR26","first-page":"1095","volume":"374","author":"MA Pfeffer","year":"2016","unstructured":"Pfeffer MA, Claggett B, Probstfield JL (2016) Lixisenatide in type 2 diabetes and acute coronary syndrome. N Engl J Med 374:1095\u20131096","journal-title":"N Engl J Med"},{"key":"4496_CR27","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMc1600140","volume":"374","author":"Y Tsutsumi","year":"2016","unstructured":"Tsutsumi Y, Tsujimoto Y, Ikenoue T (2016) Lixisenatide in type 2 diabetes and acute coronary syndrome. N Engl J Med 374:1094\u20131095","journal-title":"N Engl J Med"},{"key":"4496_CR28","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","volume":"374","author":"KB Filion","year":"2016","unstructured":"Filion KB, Azoulay L, Platt RW et al (2016) A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 374:1145\u20131154","journal-title":"N Engl J Med"},{"key":"4496_CR29","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","volume":"385","author":"RE Gilbert","year":"2015","unstructured":"Gilbert RE, Krum H (2015) Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy. Lancet 385:2107\u20132117","journal-title":"Lancet"},{"key":"4496_CR30","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCULATIONAHA.115.015853","volume":"132","author":"A Pandey","year":"2015","unstructured":"Pandey A, Garg S, Khunger M et al (2015) Dose-response relationship between physical activity and risk of heart failure: A meta-analysis. Circulation 132:1786\u20131794","journal-title":"Circulation"},{"key":"4496_CR31","volume-title":"2008 physical activity guidelines for americans","author":"U.S. Department of Health and Human Services","year":"2008","unstructured":"U.S. Department of Health and Human Services (2008) 2008 physical activity guidelines for americans. https:\/\/health.gov\/paguidelines\/ . Zugegriffen: 01.09.2016"},{"key":"4496_CR32","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G et\u00a0al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436\u20132448","journal-title":"N Engl J Med"},{"key":"4496_CR33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 36:657\u2013668","journal-title":"Eur Heart J"},{"key":"4496_CR34","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"key":"4496_CR35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00005344-199801000-00017","volume":"31","author":"MT Rademaker","year":"1998","unstructured":"Rademaker MT, Charles CJ, Espiner EA et al (1998) Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: Role of natriuretic peptides and angiotensin ii. J Cardiovasc Pharmacol 31:116\u2013125","journal-title":"J Cardiovasc Pharmacol"},{"key":"4496_CR36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR et\u00a0al (2004) Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. Enalapril (octave) trial. Am J Hypertens 17:103\u2013111","journal-title":"Am J Hypertens"},{"key":"4496_CR37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Califf RM, Konstam MA et\u00a0al (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: The omapatrilat versus enalapril randomized trial of utility in reducing events (overture). Circulation 106:920\u2013926","journal-title":"Circulation"},{"key":"4496_CR38","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","volume":"81","author":"TH Langenickel","year":"2016","unstructured":"Langenickel TH, Tsubouchi C, Ayalasomayajula S et al (2016) The effect of lcz696 (sacubitril\/valsartan) on amyloid-beta concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol 81:878\u2013890","journal-title":"Br J Clin Pharmacol"},{"key":"4496_CR39","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/eurheartj\/ehv015","volume":"36","author":"N Vodovar","year":"2015","unstructured":"Vodovar N, Paquet C, Mebazaa A et\u00a0al (2015) Neprilysin, cardiovascular, and alzheimer\u2019s diseases: The therapeutic split? Eur Heart J 36:902\u2013905","journal-title":"Eur Heart J"},{"issue":"10","key":"4496_CR40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Packer M et al (2016) Efficacy of sacubitril\/valsartan vs. Enalapril at lower than target doses in heart failure with reduced ejection fraction: The paradigm-hf trial. Eur J Heart Fail 18(10):1228\u20131234","journal-title":"Eur J Heart Fail"},{"key":"4496_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw226","author":"SL Kristensen","year":"2016","unstructured":"Kristensen SL, Martinez F, Jhund PS et al (2016) Geographic variations in the paradigm-hf heart failure trial. Eur Heart J. doi: 10.1093\/eurheartj\/ehw226","journal-title":"Eur Heart J"},{"key":"4496_CR42","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","volume":"361","author":"AJ Moss","year":"2009","unstructured":"Moss AJ, Hall WJ, Cannom DS et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329\u20131338","journal-title":"N Engl J Med"},{"key":"4496_CR43","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","volume":"363","author":"AS Tang","year":"2010","unstructured":"Tang AS, Wells GA, Talajic M et al (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363:2385\u20132395","journal-title":"N Engl J Med"},{"key":"4496_CR44","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"MR Bristow","year":"2004","unstructured":"Bristow MR, Saxon LA, Boehmer J et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140\u20132150","journal-title":"N Engl J Med"},{"key":"4496_CR45","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","volume":"352","author":"JG Cleland","year":"2005","unstructured":"Cleland JG, Daubert JC, Erdmann E et\u00a0al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539\u20131549","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-016-4496-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T23:50:56Z","timestamp":1498348256000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-016-4496-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,17]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["4496"],"URL":"https:\/\/doi.org\/10.1007\/s00059-016-4496-3","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,17]]}}}